Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × Atrasentan × Genitourinary × Clear all

Phase

Status

Sponsor Class

INDUSTRY 4 OTHER 1 NIH 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Genitourinary 1 CNS 1

Conditions

Prostatic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 50 Specimen Handling 44 aldesleukin 32 Docetaxel 30 Biopsy 27 Bevacizumab 23 Cyclophosphamide 21 Radiotherapy 19 Gemcitabine 19 Prednisone 16 Cisplatin 16 Interferon-alpha 14 Carboplatin 14 sargramostim 12 ixabepilone 12 Sorafenib 12 Paclitaxel 12 PROSTVAC 12 fludarabine phosphate 11 fludarabine 11 Fluorouracil 11 cabozantinib 10 Nivolumab 10 Immunoglobulin G 10 Goserelin 10 Disulfides 10 Sunitinib 9 Radiation 9 Ipilimumab 9 Fluorodeoxyglucose F18 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00046943 2011-02-21

Atrasentan in Treating Patients With Prostate Cancer

National Cancer Institute (NCI)

Phase 3 Completed

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡